Recent advances in pediatric acute lymphoblastic and myeloid leukemia

Current Opinion in Oncology

Volumn 15, Issue 1, 2003, Pages 23-35

  Ravindranath, Yaddanapudi ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DRUG METABOLIZING ENZYME; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RASBURICASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CELL CLONE; CHILD; CHILDHOOD CANCER; CLINICAL OBSERVATION; DOWN SYNDROME; DRUG MEGADOSE; DRUG METABOLISM; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MORTALITY; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CHILD; CHROMOSOME ABERRATIONS; CLINICAL TRIALS; CYTARABINE; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MITOXANTRONE; NEOPLASM, RESIDUAL; TUMOR MARKERS, BIOLOGICAL;

EID: 0037246483     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200301000-00004     Document Type: Review

References (149)

1. Taub JW, Konrad MA, Ge Y, et al.: High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood 2002, 99:2992-2996. • First publication from the United States on the subject. Using leukemia or patient-specific immunoglobulin heavy chain gene rearrangements, leukemic clones were detected in cord blood samples from nearly 70% of a large cohort of childhood ALL cases with hyperdiploidy followed at Children's Hospital of Michigan in Detroit, confirming the original observations of Greaves et al. [2,3,6] from the United Kingdom.
2. Gale KB, Ford AM, Repp R, et al.: Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 1997, 94:13950-13954.
3. Wiemels JL, Ford AM, Van Wering ER, et al.: Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999, 94:1057-1062.
4. Fasching K, Panzer S, Haas OA, et al.: Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse types of early childhood acute lymphoblastic leukemia. Blood 2000, 95:2722-2724.
5. Panzer-Grumayer ER, Fasching K, Panzer S, et al.: Nondisjunction of chromosomes leading to hyperdiploid childhood B-cell precursor acute lymphoblastic leukemia is an early event during leukemogenesis. Blood 2002, 100:347-349.
6. Mori H, Colman SM, Xiao Z, et al.: Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A 2002, 99:8242-8247. • A highly significant follow up study from the Greaves group, providing further evidence for fetal origin of childhood leukemia (ALL/AML) and perhaps all childhood cancer. Leukemia translocation-associated hybrid gene proteins were detected in approximately 1 of every 100 normal cord blood samples, nearly 100 times the frequency of clinical disease.
7. Knudson AG: Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001, 1:157-162.
8. Greaves MF: Etiology of acute leukaemia. Lancet 1997, 349:344-349.
9. Greaves M: Childhood leukaemia. BMJ 2002, 324:283-287.
10. Alessandri AJ, Reid GS, Bader SA, et al.: ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. Br J Haematol 2002, 116:266-272.
11. Krajinovic M, Labuda D, Richer C, et al.: Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999, 93:1496-1501.
12. Davies SM, Robison LL, Buckley JD, et al.: Glutathione S-transferase polymorphisms in children with myeloid leukemia: a Children's Cancer Group study. Cancer Epidemiol Biomarkers Prev 2000, 9:563-566.
13. Davies SM, Bhatia S, Ross JA, et al.: Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002, 100:67-71.
14. Wiemels JL, Pagnamenta A, Taylor G, et al.: A lack of a functional NAD(P)H: quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 1999, 59:4095-4099.
15. Ross JA: Maternal diet and infant leukemia: a role for DNA topoisomerase II inhibitors? Int J Cancer Suppl 1998, 11:26-28.
16. Krajinovic M, Labuda D, Mathonnet G, et al.: Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002, 8:802-810.
17. Anderer G, Schrappe M, Brechlin AM, et al.: Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000, 10:715-726.
18. Stanulla M, Schrappe M, Brechlin AM, et al.: Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 2000, 95:1222-1228.
19. Davies SM, Robison LL, Buckley JD, et al.: Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001, 19:1279-1287.
20. Smith M, Arthur D, Camitta B, et al.: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996, 14:18-24.
21. Felix CA, Lange BJ, Chessells JM: Pediatric acute lymphoblastic leukemia: Challenges and controversies in 2000. Hematology (Am Soc Hematol Educ Program) 2000:285-302. • Outstanding review of the importance of prognostic factors in childhood ALL.
22. Donadieu J, Auclerc MF, Baruchel A, et al.: Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle Group. French Acute Lymphoblastic Leukaemia Study Group. Br J Haematol 1998, 102:729-739.
23. Harris MB, Shuster JJ, Carroll A, et al.: Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992, 79:3316-3324.
24. Kaspers GJ, Pieters R, Van Zantwijk CH, et al.: Clinical and cell biologic features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 1995, 19:407-416.
25. Pieters R, den Boer ML, Durian M, et al.: Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia: implications for treatment of infants. Leukemia 1998, 12:1344-1348.
26. Kaspers GJ, Smets LA, Pieters R, et al.: Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995, 85:751-756.
27. Kaspers GJ, Veerman AJ, Pieters R, et al.: In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997, 90:2723-2729.
28. Schmiegelow K, Nyvold C, Seyfarth J, et al.: Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by POR correlates with in vitro prednisolone resistance. Leukemia 2001, 15:1066-1071.
29. Donadieu J, Hill C: Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review. Br J Haematol 2001, 115:34-45.
30. Neale GA, Coustan-Smith E, Pan Q, et al.: Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999, 13:1221-1226.
31. Szczepanski T, Orfao A, van der Velden VH, et al.: Minimal residual disease in leukaemia patients. Lancet Oncol 2001, 2:409-417.
32. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al.: TEL-AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000, 96:1094-1099.
33. Seeger K, Adams HP, Buchwald D, et al.: TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 1998, 91:1716-1722.
34. Loh ML, Silverman LB, Young ML, et al.: Incidence of TEL-AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998, 92:4792-4797.
35. Maloney K, McGavran L, Murphy J, et al.: TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia 1999, 13:1708-1712.
36. Rubnitz JE, Behm FG, Wichlan D, et al.: Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999, 13:19-21.
37. Loh ML, Rubnitz JE: TEL-AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol 2002, 9:345-352. • Discusses the controversy over the prognostic value of TEL-AML1 in childhood ALL and its relation to therapy.
38. Seeger K, Stackelberg AV, Taube T, et al.: Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol 2001, 19:3188-3193. • Discusses the controversy over the prognostic value of TEL-AML1 in childhood ALL and its relation to therapy.
39. Ford AM, Fasching K, Panzer-Grumayer ER, et al.: Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood 2001, 98:558-564.
40. Gurney JG, Ross JA, Wall DA, et al.: Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997, 19:428-432.
41. Yeoh EJ, Ross ME, Shurtleff SA, et al.: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
42. Armstrong SA, Staunton JE, Silverman LB, et al.: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002, 30:41-47. • This article and [43·] establish the need for looking at ALL with 11 q23 as a separate entity and provide a comprehensive review of current treatment results.
43. Pui CH, Gaynon PS, Boyett JM, et al.: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11 q23 chromosomal region. Lancet 2002, 359:1909-1915. • See [42·].
44. Bowman WP, Shuster JJ, Gook B, et al.: Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol 1996, 14:1252-1261.
45. Patte C, Auperin A, Michon J, et al.: The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370-3379.
46. Patte C, Philip T, Rodary C, et al.: High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991, 9:123-132.
47. Masera G, Jankovic M, Zurlo MG, et al.: Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982, 100:152-155.
48. Nishida Y, Kamatani N, Miyamoto T: Hypouricaemic effect after oral administration in chickens of polyethylene glycol-modified uricase entrapped in liposomes. J Pharm Pharmacol 1984, 36:354-355.
49. Patte C, Sakiroglu O, Sommelet D: European experience in the treatment of hyperuricemia. Semin Hematol 2001, 38:9-12. • Comprehensive review of urate oxidase in the prevention and treatment of hyperuricemia and TLS in childhood ALL.
50. Pui CH: Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001, 38:13-21.
51. Pui CH, Jeha S, Irwin D, et al.: Recombinant urate oxidase (Rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001, 15:1505-1509. • Comprehensive review of urate oxidase in the prevention and treatment of hyperuricemia and TLS in childhood ALL.
52. Goldman SC, Holcenberg JS, Finklestein JZ, et al.: A randomized comparison between Rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998-3003.
53. Atra A, Gerrard M, Hobson R, et al.: Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL): results of the UKCCSG 9003 protocol. Br J Cancer 1998, 77:2281-2285.
54. Patte C, Sakiroglu C, Ansoborlo S, et al.: Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 2002, 13:789-795.
55. Pui CH, ed. Optimal treatment of malignancies associated with hyperuricemia. In Seminars in Hematology, vol 38. Edited by P YnaB. WB Saunders; 2001.
56. Smith M, Bleyer A, Crist W, et al.: Uniform criteria for childhood acute lymphoblastic leukemia risk classification. J Clin Oncol 1996, 14:680-681. • Outstanding review of the importance of prognostic factors in childhood ALL.
57. Donadieu J, Auclerc MF, Baruchel A, et al.: Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia: analysis of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE). Br J Cancer 2000, 83:1617-1622.
58. Jones B, Freeman Al, Shuster JJ, et al.: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991, 19:269-275.
59. Kamps WA, Veerman AJ, van Wering ER, et al.: Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia 2000, 14:2240-2246.
60. Kaspers GJ, Veerman AJ, Popp-Snijders C, et al.: Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1996, 27:114-121.
61. Hurwitz GA, Silverman LB, Schorin MA, et al.: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000, 88:1964-1969. • An important cautionary note with regard to increased toxicity associated with dexamethasone in place of prednisone for induction of remission in childhood ALL.
62. Ray M, Marwaha RK, Trehan A: Chemotherapy related fatal neurotoxicity during induction in acute lymphoblastic leukemia. Indian J Pediatr 2002, 69:185-187.
63. Barr RD, Guo CY, Wiernikowski J, et al.: Osteopenia in children with acute lymphoblastic leukemia: a pilot study of amelioration with pamidronate. Med Pediatr Oncol 2002, 39:44-46.
64. Mattano LA Jr, Sather HN, Trigg ME, et al.: Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000, 18:3262-3272.
65. McGrath P, Pitcher L: "Enough is enough": qualitative findings on the impact of dexamethasone during reinduction/consolidation for pediatric acute lymphoblastic leukaemia. Support Care Cancer 2002, 10:146-155.
66. Verrips A, Rotteveel JJ, Lippens R: Dexamethasone-induced hepatomegaly in three children. Pediatr Neurol 1998, 19:388-391.
67. Wolff JE, Hauch H, Kuhl J, et al.: Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Res 1998, 18:2895-2899.
68. Amylon MD, Shuster J, Pullen J, et al.: Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999, 13:335-342.
69. Pui CH, Relling MV, Behm FG, et al.: L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995, 9:1680-1684.
70. Gustafsson G, Schmiegelow K, Forestier E, et al.: Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of GNS irradiation. Nordic Society of Pediatric Hematology and Oncology (NOPHO). Leukemia 2000, 14:2267-2275.
71. Mahoney DH Jr, Shuster JJ, Nitschke R, et al.: Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 2000, 18:1285-1294.
72. Harris MB, Shuster JJ, Pullen J, et al.: Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia 2000, 14:1570-1576.
73. Relling MV, Rubnitz JE, Rivera GK, et al.: High incidence of secondary brain tumors after radiotherapy and antimetabolites. Lancet 1999, 354:34-39.
74. Loning L, Zimmermann M, Reiter A, et al.: Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000, 95:2770-2775.
75. Schrappe M, Reiter A, Ludwig WD, et al.: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000, 95:3310-3322.
76. Kamps WA, Bokkerink JP, Hahlen K, et al.: Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 1999, 94:1226-1236.
77. Maloney KW, Shuster JJ, Murphy S, et al.: Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000, 14:2276-2285.
78. Pui CH, Boyett JM, Rivera GK, et al.: Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000, 14:2286-2294.
79. Pui CH, Mahmoud HH, Rivera GK, et al.: Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998, 92:411-415.
80. Pollock BH, DeBaun MR, Camitta BM, et al.: Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 2000, 18:813-823. • Beneficial role of HDMTX in certain ethnic or racial groups with ALL
81. Pui CH, Boyett JM, Hancock ML, et al.: Outcome of treatment for childhood cancer in black as compared with white children. The St Jude Children's Research Hospital experience, 1962 through 1992. JAMA 1995, 273:633-637.
82. Reiter A, Schrappe M, Ludwig WD, et al.: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic tymphoma: a BFM group report. Blood 2000, 95:416-421.
83. Schrappe M, Reiter A, Zimmermann M, et al.: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000, 14:2205-2222.
84. Matherly LH, Taub JW, Ravindranath Y, et al.: Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 1995, 85:500-509.
85. Taub JW, RY, Ekizian R, et al.: Elevated dihydrofolate reductase levels are a common finding in African American children with B-precursor acute lymphoblastic leukemia at diagnosis: a potential mechanism leading to treatment failure. Blood 1996, 88:166a.
86. Rozen R: Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997, 78:523-526.
87. Bagley PJ, Selhub J: A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci U S A 1998, 95:13217-13220.
88. van Ede AE, Laan RF, Blom HJ, et al.: The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:2525-2530.
89. Ulrich CM, Yasui Y, Storb R, et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001, 98:231-234.
90. Schmiegelow K, Pulczynska M: Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer 1990, 61:767-772.
91. Taub JW, Matherly LH, Ravindranath Y, et al.: Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia 2002, 16:764-765.
92. Lennard L, Lilleyman JS, Van Loon J, et al.: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990, 336:225-229.
93. McLeod HL, Krynetski EY, Relling MV, et al.: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000, 14:567-572.
94. Schmiegelow K, Bretton-Meyer U: 6-Mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Leukemia 2001, 15:74-79.
95. Coulthard SA, Hogarth LA, Little M, et al.: The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002, 52:102-109. • Outstanding review of the role of TPMT in the pharmacology of 6-mercaptopurine and 6-thiogaunine.
96. Dervieux T, Blanco JG, Krynetski EY, et al.: Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001, 61:5810-5816.
97. Broxson EH, DM, Wong R, et al.: Portal hypertension develops in a subset of children treated with maintenance oral 6-thioguanine for standard risk acute lymphoblastic leukemia. Blood 2001, 98:113a.
98. Bo J, Schroder H, Kristinsson J, et al.: Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999, 86:1080-1086.
99. Greenlee RT, Hill-Harmon MB, Murray T, et al.: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-35.
100. Perel Y, Auvrignon A, Leblanc T, et al.: Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. J Clin Oncol 2002, 20:2774-2782. • This article and [102·] discuss new strategies for remission induction in childhood AML.
101. Behar C, Suciu S, Benoit Y, et al.: Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872. Med Pediatr Oncol 1995, 26:173-179.
102. Creutzig U, Ritter J, Zimmermann M, et al.: Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001, 19:2705-2713. • See [100·].
103. Stevens RF, Hann IM, Wheatley K, et al.: Marked improvements in outcome with chemotherapy alone in pediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998, 101:130-140.
104. Ravindranath Y, Abella E, Krischer JP, et al.: Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992, 80:2210-2214.
105. Bloomfield CD: Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia 1992, 6(suppl 4):65-67.
106. Bloomfield CD, Lawrence D, Byrd JC, et al.: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58:4173-4179.
107. Lowenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1052.
108. Degos L: Differentiating agents in the treatment of leukemia. Leuk Res 1990, 14:717-719.
109. Degos L, Wang ZY: All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001, 20:7140-7145.
110. Tallman MS, Nabhan C, Feusner JH, et al.: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002, 99:759-767.
111. Warrell RP Jr, de The H, Wang ZY, et al.: Acute promyelocytic leukemia. N Engl J Med 1993, 329:177-189.
112. Grimwade D, Walker H, Oliver F, et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
113. Chang M, Raimondi SC, Ravindranath Y, et al.: Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Leukemia 2000, 14:1201-1207.
114. Creutzig U, Zimmermann M, Ritter J, et al.: Definition of a standard-risk group in children with AML. Br J Haematol 1999, 104:630-639.
115. Gilliland DG, Griffin JD: The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542. • A timely comprehensive review of the newest prognostic marker in AML, the receptor tyrosine kinase FLT3.
116. Thiede C, Steudel C, Mohr B, et al.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
117. Liang DC, Shih LY, Hung U, et al.: Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer 2002, 94:3292-3298.
118. Meshinchi S, Woods WG, Stirewalt DL, et al.: Prevalence and prognostic significance of Flt3 intemal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.
119. Whitman SP, Archer KJ, Feng L, et al.: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001, 51:7233-7239.
120. Creutzig U, Ritter J, Schellong G: Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990, 75:1932-1940.
121. Ritter J, Creutzig U, Schellong G: Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group. Leukemia 1992, 6(suppl 2):59-62.
122. Ravindranath Y, Steuber CP, Krischer J, et al.: High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol 1991, 9:572-580.
123. Ravindranath Y, Yeager AM, Chang MN, et al.: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1995, 334:1428-1434.
124. Hann IM, Stevens RF, Goldstone AH, et al.: Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997, 89:2311-2318.
125. Woods WG, Kobrinsky N, Buckley JD, et al.: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996, 87:4979-4989.
126. Woods WG, Neudorf S, Gold S, et al.: A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001, 97:56-62.
127. Lie SO, Jonmundsson G, Mellander L, et al.: A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Pediatric Hematology and Oncology (NOPHO). Br J Haematol 1996, 94:82-88.
128. Michel G, Baruchel A, Tabone MD, et al.: Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia: a prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Hematol Cell Ther 1996, 38:169-176.
129. Dordelmann M, Schrappe M, Reiter A, et al.: Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998, 12:645-651.
130. Lange B: The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000, 110:512-524.
131. Lange BJ, Kobrinsky N, Barnard DR, et al.: Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998, 91:608-615.
132. Gamis AS, Howells WB, DeSwarte-Wallace J, et al.: Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's Cancer Group Study CCG-2891. J Clin Oncol 2000, 18:1845-1855.
133. Steuber CP, Culbert SJ, Ravindranath Y, et al.: Therapy of childhood acute nonlymphocytic leukemia: the Pediatric Oncology Group experience (1977-1988). Hamatol Bluttransfus 1990, 33:198-209.
134. Creutzig U, Ritter J, Riehm H, et al.: The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis. Hamatol Bluttransfus 1987, 30:71-75.
135. Becton D, RY, Dahl GV, et al.: A phase III study of intensive oytarabine (Ara-C) induction followed by cyclosporine (CSA) modulation of drug resistance in de novo pediatric AML: POG 9421. Blood 2001, 98(suppl 1):311a.
136. Creutzig U, Ritter J, Zimmermann M, et al.: Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia 2001, 15:348-354.
137. Gieseler F, Nussler V, Brieden T, et al.: Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death. Int J Clin Pharmacol Ther 1998, 36:25-28.
138. Bishop JF, Matthews JP, Young GA, et al.: Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998, 28:315-327.
139. Weick JK, Kopecky KJ, Appelbaum FR, et al.: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996, 88:2841-2851.
140. Burnett AK, Goldstone AH, Stevens RM, et al.: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998, 351:700-708.
141. Zittoun RA, Mandelli F, Willemze R, et al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995, 332:217-223.
142. Cassileth PA, Harrington DP, Appelbaum FR, et al.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339:1649-1658.
143. Harousseau JL, Cahn JY, Pignon B, et al.: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997, 90:2978-2986.
144. Abella E, Ravindranath Y: Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation. Curr Oncol Rep 2000, 2:529-538.
145. Loeb DM, Bowers DC, Civin CI, et al.: Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood
146. Capizzi RL, Powell BL: Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias. Semin Oncol 1987, 14:40-50.
147. Capizzi RL, Davis R, Powell B, et al.: Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 1988, 6:499-508.
148. Wells RJ, Odom LF, Gold SH, et al.: Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relation to multidrug resistance gene 1. Med Pediatr Oncol 1994, 22:244-249.
149. Dahl GV, Lacayo NJ, Brophy N, et al.: Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol 2000, 18:1867-1875.